The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
CCG-1423: a small-molecule inhibitor of RhoA transcriptional signaling
Abstract
Lysophosphatidic acid receptors stimulate a Gα12/13/RhoA-dependent gene transcription program involving the serum response factor (SRF) and its coactivator and oncogene, megakaryoblastic leukemia 1 (MKL1). Inhibitors of this pathway could serve as useful biological probes and potential cancer therapeutic agents. Through a transcription-based high-throughput serum response element-luciferase screening assay, we identified two small-molecule inhibitors of this pathway. Mechanistic studies on the more potent CCG-1423 show that it acts downstream of Rho because it blocks SRE.L-driven transcription stimulated by Gα12Q231L, Gα13Q226L, RhoA-G14V, and RhoC-G14V. The ability of CCG-1423 to block transcription activated by MKL1, but not that induced by SRF-VP16 or GAL4-VP16, suggests a mechanism targeting MKL/SRF-dependent transcriptional activation that does not involve alterations in DNA binding. Consistent with its role as a Rho/SRF pathway inhibitor, CCG-1423 displays activity in several in vitro cancer cell functional assays. CCG-1423 potently (<1 μmol/L) inhibits lysophosphatidic acid–induced DNA synthesis in PC-3 prostate cancer cells, and whereas it inhibits the growth of RhoC-overexpressing melanoma lines (A375M2 and SK-Mel-147) at nanomolar concentrations, it is less active on related lines (A375 and SK-Mel-28) that express lower levels of Rho. Similarly, CCG-1423 selectively stimulates apoptosis of the metastasis-prone, RhoC-overexpressing melanoma cell line (A375M2) compared with the parental cell line (A375). CCG-1423 inhibited Rho-dependent invasion by PC-3 prostate cancer cells, whereas it did not affect the Gαi-dependent invasion by the SKOV-3 ovarian cancer cell line. Thus, based on its profile, CCG-1423 is a promising lead compound for the development of novel pharmacologic tools to disrupt transcriptional responses of the Rho pathway in cancer. [Mol Cancer Ther 2007;6(8):2249–60]
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhang, J.-H., Chung, T. D. Y., & Oldenburg, K. R. (1999) · SLAS Discovery · doi:10.1177/108705719900400206 · Cited by 6,847
Rational design and characterization of a Rac GTPase-specific small molecule inhibitor
Gao, Y., Dickerson, J. B., Guo, F., Zheng, J., & Zheng, Y. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307512101 · Cited by 1,091
RGS-containing RhoGEFs: the missing link between transforming G proteins and Rho?
Fukuhara, S., Chikumi, H., & Gutkind, J. S. (2001) · Oncogene · doi:10.1038/sj.onc.1204182 · Cited by 219
Cited by
Zhou, Y., Huang, X., Hecker, L., Kurundkar, D., Kurundkar, A., Liu, H., Jin, T.-H., Desai, L., Bernard, K., & Thannickal, V. J. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66700 · Cited by 455
Cardiac fibrosis: new insights into the pathogenesis
Ma, Z.-G., Yuan, Y.-P., Wu, H.-M., Zhang, X., & Tang, Q.-Z. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.28103 · Cited by 331
Li, H., Wang, X., Wen, C., Huo, Z., Wang, W., Zhan, Q., Cheng, D., Chen, H., Deng, X., Peng, C., et al. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0738-0 · Cited by 260
MRTF potentiates TEAD‐YAP transcriptional activity causing metastasis
Kim, T., Hwang, D., Lee, D., Kim, J., Kim, S., & Lim, D. (2017) · The EMBO Journal · doi:10.15252/embj.201695137 · Cited by 114
Miranda, M. Z., Bialik, J. F., Speight, P., Dan, Q., Yeung, T., Szászi, K., Pedersen, S. F., & Kapus, A. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.780502 · Cited by 103
Metadata
- Authors
- Evelyn, C. R., Wade, S. M., Wang, Q., Wu, M., Iñiguez-Lluhí, J. A., Merajver, S. D., & Neubig, R. R.
- Venue
- Molecular Cancer Therapeutics
- Published
- 2007-08-01
- Volume
- 6
- Issue
- 8
- Pages
- 2249-2260
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2114051326
- Cited by
- 200
- References
- 3
- FWCI
- 1.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CCG-1423: a small-molecule inhibitor of RhoA transcriptional signaling. https://app.cochat.ai/papers/10.1158/1535-7163.mct-06-0782
- The paper
- Evelyn, C. R., Wade, S. M., Wang, Q., Wu, M., Iñiguez-Lluhí, J. A., Merajver, S. D., & Neubig, R. R. (2007). CCG-1423: a small-molecule inhibitor of RhoA transcriptional signaling. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-06-0782
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.